“Securing clinical supply is of significant importance to execute our ambitious clinical development plans. Precirix is currently running a Phase I/II trial and advancing its second pipeline product to the clinic.”, said Ruth Devenyns, Chief Executive Officer of Precirix, “We are excited to start working with IFE, a leader in the field of radiopharmaceutical manufacturing. With this third supplier on board, we will be able to cover North-America as well as Europe, the major regions targeted in our clinical trials.”
Erik Flatmark, Director Radiopharmacy division at IFE commented, “Precirix’ platform of iodinated sdAbs is proving to be a solid platform technology. We look forward to working with the company and contribute to bringing these innovative radiopharmaceuticals to patients.”
About Precirix NV
Precirix is a private, clinical-stage biopharmaceutical company dedicated to extending and improving the lives of cancer patients by designing and developing precision radiopharmaceuticals, using camelid single-domain antibodies labeled with radioisotopes. The company has a broad pipeline with one product candidate in a Phase I/II clinical trial and two in advanced preclinical stage. Research on multiple isotopes, linker technology and combination therapies further expand the platform. Precirix’ technology also allows for a theranostic approach, where patients can be selected using a low dose/imaging version of the product, followed by a higher therapeutic dose for treatment.
The Institute for energy technology (IFE) was founded by the Norwegian Government in 1948 to develop Norway’s nuclear research. Norway was a pioneer in nuclear research and was the sixth country in the world to build a nuclear reactor in 1951.
Today IFE is an independent foundation located in Kjeller and in Halden. The institute has both Norwegian and international customers and has a turnover of around NOK 1 billion a year. IFE is one of Norway’s largest research institutes with around 600 employees. IFE has leading research environments within renewable energy, digital systems, nuclear technology, radiopharmaceuticals, and industrial development.
Your browser is not supported. Update your browser for more security, speed and to make the most of this site.